Kornimate/medical-research-clean huggingface dataset:
a placebo-controlled trial of buspirone for treatment of marijuana dependence

Conditions: Marijuana Abuse

Summary: the purpose of this study is to determine if buspirone combined with motivational enhancement therapy is effective in reducing marijuana use in marijuana-dependent adults.


Eligibility criteria:
inclusion criteria: 1. healthy men and women, 18 years of age to 65 years of age. 2. meet dsm-iv criteria for marijuana dependence. 3. all subjects will agree to and sign a written, irb-approved informed consent. 4. subjects must live within a 60-mile radius of charleston, sc, in order to improve study visit compliance. 5. subjects must be willing to identify collateral individuals for contact purposes to facilitate follow-up appointments. exclusion criteria: 1. individuals meeting dsm-iv dependence for a substance other than marijuana with the exception of nicotine and caffeine. dependence on nicotine and caffeine will be allowed since dependence on these substances commonly co-occurs with marijuana dependence and excluding these individuals would compromise study recruitment. 2. individuals meeting dsm-iv criteria for a lifetime history of schizophrenia or another non-affective psychotic disorder or bipolar disorder, since these patients will most likely be taking other psychotropic medications and often require intensive psychiatric care. 3. individuals meeting dsm-iv criteria for current major depressive disorder or eating disorder, since these individuals will likely require treatment with psychotropic medications. 4. individuals who present significant suicidal risk. 5. individuals with significant cognitive impairment, as they may be unable to understand the informed consent, comply with study protocol, or accurately complete assessments. 6. individuals currently receiving benzodiazepines, antidepressant or antipsychotic medications, as these medications could confound the effects of buspirone treatment. 7. pregnant or nursing women, or women who refuse to use adequate birth control, as buspirone has not been approved for use in pregnancy. 8. individuals without stable housing, as contacting these individuals would be difficult. 9. individuals with major medical illnesses (e.g., hiv, renal failure, unstable angina, chronic obstructive pulmonary disease, infectious hepatitis). 10. individuals who, in the investigators' opinion, would not be able to comply with study procedures, such as individuals unable to reliably present for intake appointments.
efficacy and safety of bismuth quadruple therapy containing cefuroxime and tetracycline as first-line therapy for eradicating helicobacter pylori in patients allergic to penicillin

Conditions: Helicobacter Pylori Infection

Summary: the researchers collected untreated h. pylori positive patients from outpatient clinics. subjects were randomly assigned to receive either 14 days of bismuth quadruple therapy with cefuroxime and tetracycline or 14 days of bismuth quadruple therapy with cefuroxime and levofloxacin for helicobacter pylori eradication. after 6 weeks of treatment, subjects underwent another 13c urea breath test. eradication rates, adverse reaction rates and patient compliance were calculated.


Eligibility criteria:
inclusion criteria: 1. age 18-70 years old, regardless of gender. 2. history of penicillin allergy. 3. helicobacter pylori infection. 4. patients who have not previously received helicobacter pylori eradication therapy. exclusion criteria: 1. medication history of bismuth and antibiotics within 4 weeks; ppis and p-cabs within 2 weeks. 2. serious underlying diseases, such as liver insufficiency, renal insufficiency, malignant tumors, etc. 3. previous gastric or esophageal surgery. 4. history of allergy to test drugs. 5. pregnant and lactating women and those unwilling to use contraception during the trial period. 6. have other behaviors that may increase the risk such as alcohol and drug abuse. 7. those unable to provide informed consent.

Keywords: helicobacter pylori infection bismuth-containing quadruple therapy
extended bolus for meals in a closed-loop system

Conditions: Type 1 Diabetes

Summary: this study aims to evaluate whether the use of an extended bolus will improve glucose control with high-fat high protein meals using a closed-loop system. the new knowledge gained from this study may provide a method to allow for the proper administration of insulin over an extended period to mitigate the risk of prolonged hyperglycemia or early hypoglycemia.


Eligibility criteria:
inclusion criteria * age between 13 and 19 years old, a1c \> 6% at screening * diagnosed with type 1 diabetes for at least one year * total daily dose (tdd) of insulin ≥ 0.3 units/kg/day * currently using the control iq closed-loop system * willing to abide by meal recommendations and study procedures * willing and able to sign the informed consent form (icf) and/or has a parent or guardian willing and able to sign the icf * use an android or apple smartphone * willingness not to start any new non-insulin glucose-lowering agent during the course of the trial * participant and parent(s)/guardian(s) willingness to participate in all training sessions as directed by study staff * parent/guardian proficient in reading and writing english * live in the united states, with no plans to move outside the united states during the study period exclusion criteria * a1c \>10% * one or more episodes of severe hypoglycemia or dka requiring er visit or hospitalization within the past three months * used non-insulin anti-diabetic medication within the last 30 days other than metformin * known history of gastroparesis, seizure disorder, adrenal insufficiency, or ongoing renal or hepatic disease * pregnancy or lactation * untreated or unstable hypothyroidism * currently undergoing cancer treatment or systemic treatment with steroids * untreated or inadequately treated mental illness * current alcohol abuse * current illness that would interfere with participation in the study * delayed gastric emptying or any concurrent conditions that can be associated with delayed gastric emptying or altered digestion; and the use of any medication that affects gastric emptying * celiac disease
clinical trial of rasagiline in levodopa-treated parkinson's disease patients with motor fluctuations

Conditions: Parkinson´s Disease

Summary: the objective of this study is to evaluate the efficacy, tolerability, and safety of rasagiline compared to placebo in pd patients with motor fluctuations on levodopa therapy.

levodopa has been the mainstay therapy for pd for decades, and it is considered to be one of the most effective medications for relief of the symptoms of pd. however, within few months to few years the majority of levodopa-treated patients notice a decline in the duration of benefit of each dose and develop motor-complications. a major problem is the appearance of fluctuations in mobility, cycles of on and off periods. the administration of rasagiline, a mao-b inhibitor, can slow the elimination of the endogenous dopamine supplies or the dopamine produced from the exogenous levodopa therapy and may therefore improve on-off fluctuations. the objective of this study is to evaluate the efficacy, tolerability, and safety of rasagiline compared to placebo in pd patients with motor fluctuations on levodopa therapy.

Eligibility criteria:
inclusion criteria: * patients with idiopathic pd * patients receiving at least 300 mg daily doses of levodopa and not less than 8 daily doses of levodopa with the stable dose * patient with a modified hoehn and yahr stage between 2 to 4 in the off state * patient with motor fluctuations averaging at least 2 hour daily in the off state * patients who have demonstrated the ability to keep accurate 24-hour diaries exclusion criteria: * patients with parkinsonian syndrome induced by medicine, metabolic disease, encephalitis and central nervous system degenerative diseases or disease of basal ganglia * patients with severe cognitive impairment judged by a mini mental state examination * patients with a clinically significant psychiatric illness * patients with hamilton depression rating scale (hamd): total score ≤10 * patients with a clinically significant or unstable medical or surgical condition which would preclude safe and complete study participation * patients with a clinically significant or unstable vascular disease * patients with severe disabling dyskinesias other inclusion and exclusion criteria may apply

Keywords: motor fluctuations parkinson´s disease rasagiline
global anticoagulant registry in the field- venous thromboembolic events

Conditions: Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism

Summary: the protocol is a large registry to describe acute, sub-acute and extended duration of anticoagulation management, clinical and economic duration of anticoagulation management, clinical and economic outcomes in patients with treated acute vte (dvt and pe) in the real-world setting. main objectives are to clarify the: * treatment related details for acute vte (either conventional anticoagulation therapy, treatment with a direct oral anti-coagulant or other modalities of treatment) * rate of early and late symptomatic vte recurrence * rate and nature of complications of vte including post thrombotic syndrome and chronic thromboembolic pulmonary hypertension * rate of bleeding complications * rate of all-cause mortality at six months

other objectives are to clarify the additional outcomes of: * stroke (measured by number of incidences) * transient ischemic attack (tia) (measured by number on incidences) * st elevated myocardial infarction (stemi) (measured by number of incidences) * non-st elevated myocardial infraction (nstemi) (measured by number of incidences) * unstable angina (measured by number of incidences) * quality of life and patient reported outcomes and costs associated with the management of vte.

Eligibility criteria:
inclusion criteria: * written informed consent * age 18 years and over * treated first time or recurrent dvt (lower or upper extremity), pe alone or overlapping dvt and pe confirmed by appropriate diagnostic methods (patients must be assessed for eligibility within 30 days of diagnosis) * patients included with recurrent vte must have completed treatment for the previous vte episode exclusion criteria: * patients for whom long-term follow-up is not envisaged within the enrolling hospital or the associated primary care physician * patients participating in an interventional study that dictates treatments, visit frequency, or diagnostic procedures * patients with only superficial vein thrombosis (svt)

Keywords: venous, thromboembolism, embolism, dvt, pulmonary embolism, thrombosis
signal intensity gradient in cerebral arteries

Conditions: Ischemic Stroke, Acute

Summary: arterial wall shear stress (wss) contributes to atherosclerosis from its inception, progression, and disruption of plaque. however, there is no previous study for an association between cerebral artery wss and clinical outcome in patients with ischemic stroke in lenticulostriate artery. the researchers aimed to investigate whether the signal intensity gradient (sig) from time-of-flight magnetic resonance angiography (tof mra) in cerebral arteries, as a surrogate measure of arterial wss, is associated with clinical outcome, which was determined with modified rankin scale (mrs). the patients (n=294) with the lenticulostriate artery infarction were collected in 3 hospitals with variable locations and sizes (gunsan, jeonju, and seoul). for a clinical outcome, national institute of health stroke scale (nihss) and modified rankin scale (mrs) were checked serially from the date of admission. the mrs 2 or less at the 7th day or discharge was defined as a favorable outcome. the arterial sigs were measured concurrently in both internal carotid, anterior/middle/posterior cerebral, vertebral arteries, and basilar artery from tof mra on initial diagnosis. the independent association between the clinical outcome and cerebral arterial sig was analyzed adjusting for all the possible potential confounders.


Eligibility criteria:
inclusion criteria: 1. patients aged 18 years or older who had brain magnetic resonance imaging (mri) for acute ischemic stroke within 3 days 2. patients who underwent diffusion-weighted imaging (dwi) and apparent diffusion coefficient of the cerebral parenchyma, and cerebral angiographic measurements, in which, intracranial arteries should be examined by time-of-flight (tof) techniques 3. a patient with high signal intensity lesions in the unilateral lsa territory on dwi. exclusion criteria: 1. patients younger than 18 years of age 2. patients with moderate to severe (\>50%) stenosis or occlusion of the major intracranial and extracranial arteries, including internal carotid artery (ica), middle cerebral artery (mca), anterior cerebral artery (aca), posterior cerebral artery (pca), basilar artery (ba), and vertebral artery (va) 3. patients whose ischemic stroke was due to or related with cardiac or rare etiology (e.g., arterial dissection, moyamoya disease).

Keywords: cerebral artery lenticulostriate artery infarction signal intensity gradient signal intensity gradient, wall shear stress
defining the mechanisms underlying adrenal insufficiency in cirrhosis

Conditions: Cirrhosis; Adrenal Insufficiency

Summary: this study aims to define the prevalence and potential pathophysiologic mechanisms underlying relative adrenal insufficiency (rai) in outpatients with decompensated cirrhosis. patients will be followed prospectively for up to two years to determine incidence of rai, whether rai represents a permanent or dynamic physiologic state in cirrhosis, and to determine whether rai in this setting is associated with important clinical outcomes.


Eligibility criteria:
inclusion criteria: * age \>= 18y * diagnosis of cirrhosis by biopsy or compatible clinical picture * experienced at least one portal decompensating event in the past and currently have a child-pugh b or c classification exclusion criteria: * pregnant women * prisoners * not been treated with medication known to affect the adrenal axis within the past 4 weeks (oral or iv steroids, ketoconazole, etomidate) * hospitalized at time of enrollment
conversion to embeda with rescue trial

Conditions: Chronic Disease; Pain

Summary: the purpose of the research study is to find out if opioid dependent chronic pain patients who are judged by their physician to be eligible to change their current opioid medicine and to participate in this study can be successfully adjusted to a stable dose of embeda (morphine sulfate and naltrexone hydrochloride). the study will also assess each patient's risk for prescription opioid abuse, misuse and diversion.

the decision to terminate the trial was based on a lack of study drug supply. the decision was not based on any safety concerns. the termination letter was sent on 11march2011.

Eligibility criteria:
inclusion criteria: * be able to read, speak and understand english * have chronic moderate to severe pain for at least 3 months * require around the clock opioid medication for the relief of pain * have been taking a daily opioid for at least 30 days prior to starting the study * be able to be safely switched to a different pain medication * be practicing acceptable birth control methods for female patients of childbearing potential * be willing to participate in the study and able to comply with study procedures exclusion criteria: * be currently diagnosed with or participating in and/or seeking treatment for opioid and/or alcohol abuse * be allergic or intolerant to morphine, morphine salts, naltrexone or other opioids * be currently taking tramadol and/or extended release morphine products * have respiratory depression * have acute or severe bronchial asthma or severe chronic obstructive pulmonary disease * have migraines as your main source of pain * have any form of bowel obstruction * be pregnant or breast feeding * have had 2 or more surgeries for low back pain * be planning a major surgery during the study * be staying in a hospital or nursing home * be planning to have steroid injections for your chronic pain during the study * have a life expectancy of less than 2 months

Keywords: chronic pain embeda opioid moderate pain severe pain conversion converting switching morphine aberrant behavior pain (dt) + chronic disease (dt)
streamlined localization using scout® at biopsy (streamloc )

Conditions: Breast Cancer

Summary: this registry is intended to demonstrate the utility of scout® in the canadian public and us healthcare systems with fixed resources and a conservative approach to patient and clinician exposure to harm. the efficacy and safety of this system will be further assessed, as well as the acceptance of clinicians and patients.

this registry is intended to demonstrate the utility of scout® in the canadian public and us healthcare systems with fixed resources and a conservative approach to patient and clinician exposure to harm (i.e., radiation, covid-19 exposure, patient emotional trauma). by assessing the utility of reflector insertion at the time of biopsy, this study will be able to measure the impact on patient visits to the breast center for invasive procedures between biopsy and surgery, and quantify this value to the public healthcare system. the efficacy and safety of this system will be further assessed, as well as the acceptance of clinicians and patients.

Eligibility criteria:
inclusion criteria: 1. woman \>18 years and \< 80 years of age; 2. classified as breast imaging reporting and data system (bi-rads) 4c or 5; 3. lesion depth is \< 6 cm from skin surface; 4. non-palpable lesions; 5. informed consent obtained. exclusion criteria: 1. multicentric breast cancer; 2. pregnant or lactating; 3. known or suspected nickel-titanium allergy.
evaluation of somatostatin receptor expression in pet 68ga-dotatoc in patients followed for metastatic breast cancer

Conditions: Breast Cancer Metastatic

Summary: dotabreast: evaluation of somatostatin receptor expression in pet 68ga-dotatoc in patients followed for metastatic breast cancer this is a prospective, monocentric, non-controlled, non-randomized, open-label, interventional study.

in women, breast cancer is the 1st largest cancer and accounted for 31% of new cancer cases in women in 2017. with 11,913 deaths in 2015, breast cancer is the 1st largest cancer death in women (19%) and the 3rd largest cancer death (men and women included) after lung and colorectal cancer. at initial diagnosis at any stage, approximately 31% of patients have regional lymph node involvement and 5 to 10% present metastatic involvement from the outset. progression to a metastatic form occurs in about 20% of cases. the risk of metastatic evolution is variable depending on the histological subtype and is a major prognostic event directly impacting overall survival. dotatoc-68ga pet scans allows in vivo evaluation of sst2 somatostatin receptor expression. its use is widely validated in clinical practice for the assessment of extension of neuroendocrine tumors. it is also being used to evaluate the feasibility of sst2-targeted internal radiotherapy therapy with lutathera (177lu-oxodotreotide) in patients with metastatic small intestine neuroendocrine tumours.

Eligibility criteria:
inclusion criteria: * age over 18 * patients with metastatic breast cancer who have completed at least one first line of systemic therapy for metastatic breast cancer * patient labeled on the primary lesion er+her2- (20) * presence of metastatic liver and bone lesions identifiable with 18f-fdg pet-scan * presence of at least 10 identifiable secondary lesions in 18f-fdg pet-scan * no therapeutic change between 18f-fdg pet-scan and 68ga-dotatoc pet-scan. * performing the pet scan with 68ga-dotatoc within a maximum of 21 days after the 18f-fdg pet-scan * person affiliated to or benefiting from social security * person who has given written informed consent exclusion criteria: * patients followed or with history of other active neoplastic pathology (including neuroendocrine tumor) * known allergy to 68ga-dotatoc or its excipients * subject refusing to sign the consent to participate * minor subject * subject excluded from another study * persons referred to articles l1121-5 to l1121-8 of the public health code (csp) * subject cannot be contacted in case of emergency

Keywords: breast cancer metastatic somatostatin receptor expression pet-scan 68ga-dotatoc nuclear oncology 177-lu-oxodotreotide dotatoc
electrophysiological changes with diet.

Conditions: Fasting, Intermittent; Fasting Hypoglycemia; Fasting; Obesity; Diabetes

Summary: dietary habits may affect our body by certain mechanisms, visual sense is one of the most vital human senses that needs special attention in our daily habits.

retinal function directly related to our quality of vision, different drugs can affect our vision in certain ways, however, out unhealthy dietary habits can indirectly affect our quality of life and vision.

Eligibility criteria:
inclusion criteria: * healthy subjects with intermittent fasting. * obese subjects with body mass index more than 30. exclusion criteria: * patients with any retinal diseases that may ter retinal functional test. * patients on systemic drugs that may alter retinal function.

Keywords: fasting ramadan diet retina electroretinogram
protein supplementation of snakehead fish cookies on pregnant women

Conditions: Pregnancy Related

Summary: this study was randomized controlled trial study whose subjects were pregnant women in sleman district, yogyakarta, indonesia. the aims of this study were to make snakehead fish cookies formula which can be well accepted by pregnant women and to observed its effect on fetal growth and birth weight and length. it was hypothesized that snakehead fish cookies could prevent intrauterine fetal growth (iugr) and low birth weight (lbw). subjects on this study were randomly allocated into two groups which were treatment and control group. subjects in treatment group were given snakehead fish cookies, while subject in control group received standard cookies. the intervention period lasted until subjects delivered their babies.

subjects were enrolled from public health center (puskesmas) in sleman district, yogyakarta province, indonesia. subjects were being explained about the study intervention and were given informed consent as an approval of joining this study. the intervention was given everyday as much as 75g cookies for several weeks period (until delivery). examination on fetal growth was done every month for each subjects. birth weight and length were collected after delivery from child health book record.

Eligibility criteria:
inclusion criteria: 1. second and third trimester gestational age, 2. lower-class family with income under sleman district minimum wage in 2019 (\< 1,701,000 rupiah), 3. pregnant women of under 25 years old, and 4. high school graduate or below exclusion criteria: 1. suffering from anemia, 2. experiencing preeclampsia, 3. having multiple gestational, and 4. allergic to fish, eggs, and chocolate.

Keywords: snakehead fish cookies intrauterine fetal growth low birth weight randomized controlled trial protein supplementation